drugset
drugset / Trial / NCT04112498

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

NCT04112498 ↗

Phase 1 Completed 24 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors

Timeline

Start
2019-10-01
Primary completion
2023-02-27
Completion
2023-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody — —
Subject Relatlimab Monoclonal antibody — —
Background rHuPH20 Protein / enzyme biologic — —

Indications

cancer